Recent studies have revealed that EGFR mutations can profoundly alter the tumor immune microenvironment, promoting immunosuppressive cells including myeloid-derived suppressor cells, an increased expression of regulatory T cells, and alterations in cytokine profiles (3, 4). The gene discussed is EGFR; the disease is neoplasm.